All News
PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate)
https://t.co/sUXTXDXrFh
Links:
Dr. John Cush RheumNow ( View Tweet)
Patients selected to maximise response & minimise adverse events in RA & PsA trials.
What implications does this have when we interpret the data & try to apply in clinic?
#EULAR2021 https://t.co/CocKlvjme4
Dr Irwin Lim _connectedcare ( View Tweet)
Placebo response in PsA trials have more than doubled in last decade.
Due to patient characteristics, patient expectations?
Makes it very difficult to compare between trials
#EULAR2021 https://t.co/XQk4hqrYN8
Dr Irwin Lim _connectedcare ( View Tweet)
ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Moysidou et al reviewed pubmed registries/longitudinal cohort studies in PsA. 27 registries, totaling 30 countries (67% European, 26% N. American) Africa not represented. This is a call to arms for global PsA pts! #EULAR2021 @RheumNow Poster #POS1078 https://t.co/rsQYR6NFNT https://t.co/MU3FVXuRxS
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
We are truly blessed to live in an era when response to RA treatment is the norm.
(our forefathers looking on jealously from their gold and pencillinamine towers!)
real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq
Dr Irwin Lim _connectedcare ( View Tweet)
#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
Paul Studenic Stiddyo ( View Tweet)
Don’t forget to detect cardiac abnormalities in your #RA and #PsA patients! Systematic transthoracic echocardiogram show higher prevalence of diastolic dysfunction, mild mitral and pulmonary valve regurgitation vs. matched controls. #EULAR2021 @RheumNow #POS1392 https://t.co/UsvbEKBRUY
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Kragsnaes presents counter-intuitive data on the gut microbiome. Faecal microbiota transplant ineffective in treating active peripheral psoriatic arthritis, leading to WORSE outcomes. But maybe this also tells us something? @RheumNow #EULAR2021 Abstr#OP0010 https://t.co/nvDvO4Gfxc
Richard Conway RichardPAConway ( View Tweet)
OP0010 at #EULAR2021. FLORA trial: Fecal microbiota transplant as add-on Rx to MTX. Small trial showing time-to-event curves show inferiority to sham but good safety. Fascinating concept exploring gut-joint interaction. @RheumNow. https://t.co/BIOmA5z6vK
Eric Dein ejdein1 ( View Tweet)
Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
Dr. Rachel Tate uptoTate ( View Tweet)
Differences in PROs found in CORRONA(now CorEvitas) PsA/SpA registry Ax-PsA and AxSpA patients. Can we better use PROs for disease characterization/differentiation? Abstract #OP0049 #EULAR2021 @RheumNow https://t.co/uHW2FQe0A5 https://t.co/HuPPUTAC9Z
Dr. Rachel Tate uptoTate ( View Tweet)
Plenary abstract #OP0010: Fecal microbiota transplant (FMT) found to be inferior to sham in treating active peripheral PsA. No SAEs in patients treated with FMT. @RheumNow #EULAR2021 https://t.co/a5HgrJ4y1C https://t.co/Jk9FQZdn4B
Dr. Rachel Tate uptoTate ( View Tweet)
